The Nociceptin/Orphanin FQ Peptide Receptor
Herausgegeben:Ko, Mei-Chuan; Caló, Girolamo
The Nociceptin/Orphanin FQ Peptide Receptor
Herausgegeben:Ko, Mei-Chuan; Caló, Girolamo
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands. This special volume book - for the first time focusing on the NOP receptor - is designed to serve as a useful reference, stimulate more research on the N/OFQ-NOP receptor system, and lead to more development of NOP-related ligands for several therapeutic applications.
Andere Kunden interessierten sich auch für
- The Nociceptin/Orphanin FQ Peptide Receptor110,99 €
- Calcitonin Gene-Related Peptide (CGRP) Mechanisms95,99 €
- Calcitonin Gene-Related Peptide (CGRP) Mechanisms74,99 €
- Essentials of Pharmacology for Anesthesia, Pain Medicine, and Critical Care119,99 €
- The Pharmacology of Pain74,99 €
- Kim D. Rainsford (ed.)Nimesulide - Actions and Uses118,99 €
- Opioids106,99 €
-
-
-
The aim of this book is not only to introduce readers with a broad spectrum of biological actions of the NOP receptor, but also to feature a detailed look at the N/OFQ-NOP receptor system, medicinal chemistry, pharmacology, and clinical data of NOP-targeted ligands. This special volume book - for the first time focusing on the NOP receptor - is designed to serve as a useful reference, stimulate more research on the N/OFQ-NOP receptor system, and lead to more development of NOP-related ligands for several therapeutic applications.
Produktdetails
- Produktdetails
- Handbook of Experimental Pharmacology 254
- Verlag: Springer / Springer International Publishing / Springer, Berlin
- Artikelnr. des Verlages: 978-3-030-20185-2
- 1st ed. 2019
- Seitenzahl: 428
- Erscheinungstermin: 25. Juli 2019
- Englisch
- Abmessung: 241mm x 160mm x 29mm
- Gewicht: 796g
- ISBN-13: 9783030201852
- ISBN-10: 3030201856
- Artikelnr.: 56158618
- Handbook of Experimental Pharmacology 254
- Verlag: Springer / Springer International Publishing / Springer, Berlin
- Artikelnr. des Verlages: 978-3-030-20185-2
- 1st ed. 2019
- Seitenzahl: 428
- Erscheinungstermin: 25. Juli 2019
- Englisch
- Abmessung: 241mm x 160mm x 29mm
- Gewicht: 796g
- ISBN-13: 9783030201852
- ISBN-10: 3030201856
- Artikelnr.: 56158618
PART I. The N/OFQ-NOP Receptor System.- 1. The History of N/OFQ and the NOP Receptor.- 2. NOP-Targeted Peptide Ligands.- 3. NOP-Targeted Nonpeptide Ligands.- 4. Pharmacological Assays for Investigating the NOP Receptor.- 5. Electrophysiological Actions of N/OFQ.- 6. NOP Receptor Signaling Cascades.- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor.- PART II. Biological Actions of NOP Ligands.- 8.NOP-Related Mechanisms in Pain and Analgesia.- 9. NOP-Related Mechanisms in Substance Use Disorders.- 10. NOP Receptor Ligands and Parkinson's Disease.- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders.- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory.- 13. N/OFQ-NOP System in Food Intake.- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation.- 15. N/OFQ-NOP System and Airways.- 16. Effects of NOP-Related Ligands in Nonhuman Primates.- PART III. First Clinical Studies with NOP Ligands.- 17. Nociceptin/Orphanin FQ and Urinary Bladder.- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).- 20. Correction to: Electrophysiological Actions of N/OFQ.
PART I. The N/OFQ-NOP Receptor System.- 1. The History of N/OFQ and the NOP Receptor.- 2. NOP-Targeted Peptide Ligands.- 3. NOP-Targeted Nonpeptide Ligands.- 4. Pharmacological Assays for Investigating the NOP Receptor.- 5. Electrophysiological Actions of N/OFQ.- 6. NOP Receptor Signaling Cascades.- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor.- PART II. Biological Actions of NOP Ligands.- 8.NOP-Related Mechanisms in Pain and Analgesia.- 9. NOP-Related Mechanisms in Substance Use Disorders.- 10. NOP Receptor Ligands and Parkinson’s Disease.- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders.- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory.- 13. N/OFQ-NOP System in Food Intake.- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation.- 15. N/OFQ-NOP System and Airways.- 16. Effects of NOP-Related Ligands in Nonhuman Primates.- PART III. First Clinical Studies with NOP Ligands.- 17. Nociceptin/Orphanin FQ and Urinary Bladder.- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).- 20. Correction to: Electrophysiological Actions of N/OFQ.
PART I. The N/OFQ-NOP Receptor System.- 1. The History of N/OFQ and the NOP Receptor.- 2. NOP-Targeted Peptide Ligands.- 3. NOP-Targeted Nonpeptide Ligands.- 4. Pharmacological Assays for Investigating the NOP Receptor.- 5. Electrophysiological Actions of N/OFQ.- 6. NOP Receptor Signaling Cascades.- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor.- PART II. Biological Actions of NOP Ligands.- 8.NOP-Related Mechanisms in Pain and Analgesia.- 9. NOP-Related Mechanisms in Substance Use Disorders.- 10. NOP Receptor Ligands and Parkinson's Disease.- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders.- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory.- 13. N/OFQ-NOP System in Food Intake.- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation.- 15. N/OFQ-NOP System and Airways.- 16. Effects of NOP-Related Ligands in Nonhuman Primates.- PART III. First Clinical Studies with NOP Ligands.- 17. Nociceptin/Orphanin FQ and Urinary Bladder.- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).- 20. Correction to: Electrophysiological Actions of N/OFQ.
PART I. The N/OFQ-NOP Receptor System.- 1. The History of N/OFQ and the NOP Receptor.- 2. NOP-Targeted Peptide Ligands.- 3. NOP-Targeted Nonpeptide Ligands.- 4. Pharmacological Assays for Investigating the NOP Receptor.- 5. Electrophysiological Actions of N/OFQ.- 6. NOP Receptor Signaling Cascades.- 7.Regulation of the Genes Encoding the ppN/OFQ and NOP Receptor.- PART II. Biological Actions of NOP Ligands.- 8.NOP-Related Mechanisms in Pain and Analgesia.- 9. NOP-Related Mechanisms in Substance Use Disorders.- 10. NOP Receptor Ligands and Parkinson’s Disease.- 11. NOP Ligands for the Treatment of Anxiety and Mood Disorders.- 12. The Nociceptin/Orphanin FQ System and the Regulation of Memory.- 13. N/OFQ-NOP System in Food Intake.- 14. N/OFQ-NOP System in Peripheral and Central Immunomodulation.- 15. N/OFQ-NOP System and Airways.- 16. Effects of NOP-Related Ligands in Nonhuman Primates.- PART III. First Clinical Studies with NOP Ligands.- 17. Nociceptin/Orphanin FQ and Urinary Bladder.- 18. Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.- 19. Therapeutic Approaches for NOP Receptor Antagonists in Neurobehavioral Disorders: Clinical Studies in Major Depressive Disorder and Alcohol Use Disorder with BTRX-246040 (LY2940094).- 20. Correction to: Electrophysiological Actions of N/OFQ.